The Ontario Neurodegenerative Disease Research Initiative

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

522 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-07

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a province-wide collaboration studying dementia and how to improve the diagnosis and treatment of neurodegenerative diseases including:

* Alzheimer's disease (AD)
* Parkinson's disease (PD)
* amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease)
* frontotemporal lobar degeneration (FTD)
* vascular cognitive impairment, resulting from stroke (VCI)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Health in Aging, Neurodegenerative Diseases and Dementias In Ontario

NCT05062512

Neuro-Degenerative Disease Dementia

TERMINATED

Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling

NCT06529744

Dementia Alzheimer Disease Dementia With Lewy Bodies +7 more

RECRUITING

Comprehensive Assessment of Neurodegeneration and Dementia

NCT03402919

Dementia Mild Cognitive Impairment (MCI) Subjective Cognitive Impairment +7 more

RECRUITING

ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing

NCT04335994

Obstructive Sleep Apnea Alzheimer Disease Vascular Dementia +4 more

RECRUITING NA

Biomarkers in a Candian Memory Clinic

NCT06843109

Alzheimer's Disease (AD)

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a research program designed to investigate similarities and differences of dementia among five diseases that will improve the diagnosis and treatment of neurodegeneration. The focus is on diseases that are associated with dementia: Alzheimer's disease/mild cognitive impairment, Parkinson's disease, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar degeneration, and vascular cognitive impairment (resulting from stroke).

ONDRI is a province-wide collaboration between more than 50 of Ontario's world-class neurodegenerative disease researchers and clinicians, four patient advocacy groups, the industrial sector, and more than 20 clinical, academic and research centres carried out in partnership with the Ontario Brain Institute (OBI).

Instead of only studying what's unique, our long-term observational study is seeking out the common early indicators and risk factors of the five diseases.

Our mandate is to ensure that the findings from the data collected are transformed into new diagnostic methods that will help detect diseases earlier, improved clinical practice that puts patients first, and eventually new effective treatments that will slow the diseases from progressing or even prevent the disease so people can continue to enjoy the later years of their lives.

More than 600 participants will be followed for up to three years and will complete assessments for genomics, gait and balance, eye measurements, neuropsychology, and neuroimaging and will donate their data to a comprehensive integrated data management system called Brain-CODE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease Amyotrophic Lateral Sclerosis Frontotemporal Dementia Parkinson Disease Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational Cohort

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent must be obtained and documented.
* Participant must rate his/her level of proficiency in speaking and understanding English at 7 out of 10 or higher on the two LEAP-Q questions.
* Participant must have ≥ 8 years education.
* Participant with a minimum MoCA score of ≥18.

* Exception: FTD minimum MoCA score of ≥ 14.
* Participant must have a reliable Study Partner. The Study Partner must:

* Interact regularly with the participant (i.e., have contact with the participant at least once a month over the phone, email, or face-to-face);
* Know the participant well enough to answer questions about the her/his cognitive abilities, communication skills, mood, and daily functioning (i.e., known the participant for at least 2 years);
* Provide written informed consent and complete study questionnaires;
* Be willing and able to assist in compliance with study procedures (if required).
* Geographic accessibility to the study site.
* Participant must be able to walk (assistive aids may be used, e.g., cane, walker, etc.).

Exclusion Criteria

* Serious underlying disease other than the disease being studied which in the opinion of the investigator may interfere with the participant's ability to participate fully in the study.
* Any disease that would/could lead to death over the next 3 to 5 years (i.e., cardiac/renal/liver cancer) with poor prognosis.
* Participant has been diagnosed with more than one of the five diseases (AD/MCI, ALS, FTD, PD or VCI) being studied.
* History of alcohol or drug abuse, which in the opinion of the investigator, may interfere with the participant's ability to comply with the study procedures.
* Presence of any of the following clinical conditions:

* Substance abuse within the past year.
* Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease.
* AIDS or AIDS-related complex.
* Unstable psychiatric illness defined as psychosis (hallucinations or delusions) or untreated major depression within 90 days of the screening visit.
* Participant is currently enrolled in a disease modifying therapeutic (drug or interventional) trial or observational study that the Executive Committee feels would compromise study results.

Minimum Eligible Age

55 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No